摘要
目的探讨伊沙佐米对骨髓瘤肾病患者肾功能的影响。方法选取2015年6月至2020年6月就诊于我院的90例骨髓瘤肾病患者作为研究对象,按照治疗方式的不同将其分为A组、B组、C组,每组30例。A组采用一般化疗方案治疗,B组在A组的基础上采用硼替佐米治疗,C组在B组的基础上采用伊沙佐米治疗。比较三组患者治疗前、后的肾功能以及临床治疗效果、不良反应发生情况。结果治疗后,C组的Scr、BUA水平及24 h尿蛋白定量均明显低于A组、B组(P<0.05)。C组的治疗总有效率明显高于A组、B组(P<0.05)。C组的不良反应总发生率明显低于A组、B组,差异具有统计学意义(P<0.05)。结论伊沙佐米治疗骨髓瘤肾病可获得较为满意的效果,不仅能有效改善患者的肾功能,还能缓解病症,值得应用推广。
Objective To investigate the effect of isazomib on renal function in patients with myeloma nephropathy.Methods A total of 90 patients with myeloma nephropathy admitted in our hospital from June 2015 to June 2020 were selected as the research objects,and the patients were divided into group A,B and C according to the different treatment methods,with 30 cases in each group.The group A was treated with general chemotherapy regimen,the group B was treated with bortezomib on the basis of the group A,and the group C was treated with isazomib on the basis of the group B.The renal function before and after treatment,clinical therapeutic effect and occurrence of adverse reactions were compared among the three groups.Results After treatment,the levels of Scr,BUA and 24 h urinary protein quantification in the group C were significantly lower than those in the group A and the group B(P<0.05).The total effective rate of treatment in the group C was significantly higher than that in the group A and the group B(P<0.05).The total incidence of adverse reactions in the group C was significantly lower than that in the group A and the group B,the difference was statistically significant(P<0.05).Conclusion Isazomib in the treatment of myeloma nephropathy can achieve satisfactory results,it can not only effectively improve the renal function of patients,but also relieve the symptoms of the disease,which is worthy of application and promotion.
作者
赵锋
李振波
ZHAO Feng;LI Zhenbo(Baoji High-tech Hospital,Baoji 721000,China)
出处
《临床医学研究与实践》
2021年第35期65-67,共3页
Clinical Research and Practice
